参考文献:
[1] Sanders DB, Wolfe GI, Benatar M,et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016 Jul 26;87(4):419-25.
[2] 中华医学会神经病学分会神经免疫学组,中国免疫学会神经免疫学分会.中国重症肌无力诊断和治疗指南2015[J].中华神经科杂志,2015,48(11):934-940.
[3] 陈頔,彭丹涛,钱璐璐,胡欣.药物对重症肌无力的影响[J].中国神经免疫学和神经病学杂志,2015,22(1):71-75.
[4] 王维治,刘卫彬.重症肌无力管理国际共识(2016)解读[J].中华神经科杂志,2017,50(2):83-87.
[5] Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf. 2011 Oct 1;34(10):839-47.
[6] 艾司唑仑注射液说明书.
[7] MCDEX3咪哒唑仑药物专论/咪达唑仑片/注射用咪达唑仑说明书.
[8] 佐匹克隆片说明书.
[9] 右佐匹克隆片说明书.
[10] MCDEX3 普鲁卡因胺药物专论.
[11] MCDEX3 奎尼丁药物专论.
[12] 注射用A型肉毒毒素说明书.
[13] 青霉胺片说明书.
[14] 盐酸普鲁卡因片/注射液说明书.
[15] 盐酸丁卡因注射液/注射用丁卡因说明书.